10-K Filing

TEVA PHARMACEUTICAL INDUSTRIES LTD CIK: 818686 FY 2021

Filing Information

Form Type	10-K
Accession Number	`0001193125-22-032667`
Period End Date	20211231
Filing Date	20220209
Fiscal Year	2021
Fiscal Period	FY
XBRL Instance	d130792d10k_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 88 Income Statement 69 Cash Flow Statement 123 Stockholders Equity 23 Comprehensive Income 27

Balance Sheet 88 line items

Line Item	Tag	Value	Unit	Period
Allowance for credit losses	`AllowanceForDoubtfulAccountsReceivableCurrent`	$126.00M	USD	Point-in-time
Allowance for credit losses	`AllowanceForDoubtfulAccountsReceivableCurrent`	$90.00M	USD	Point-in-time
Common stock, par or stated value per share	`CommonStockParOrStatedValuePerShare`	0.10	CHF	Point-in-time
Common stock, par or stated value per share	`CommonStockParOrStatedValuePerShare`	0.10	CHF	Point-in-time
Ordinary shares, authorized	`CommonStockSharesAuthorized`	2.50B	shares	Point-in-time
Ordinary shares, authorized	`CommonStockSharesAuthorized`	2.50B	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$1.98B	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$2.18B	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$2.17B	USD	Point-in-time
Accounts receivables, net of allowance for credit losses of $90 million and $126 million as of December 31, 2021 and December 31, 2020, respectively	`AccountsReceivableNetCurrent`	$4.53B	USD	Point-in-time
Ordinary shares, issued	`CommonStockSharesIssued`	1.21B	shares	Point-in-time
Ordinary shares, issued	`CommonStockSharesIssued`	1.20B	shares	Point-in-time
Accounts receivables, net of allowance for credit losses of $90 million and $126 million as of December 31, 2021 and December 31, 2020, respectively	`AccountsReceivableNetCurrent`	$4.58B	USD	Point-in-time
Treasury shares	`TreasuryStockShares`	106.00M	shares	Point-in-time
Inventories	`InventoryNet`	$4.40B	USD	Point-in-time
Inventories	`InventoryNet`	$3.82B	USD	Point-in-time
Treasury shares	`TreasuryStockShares`	106.00M	shares	Point-in-time
Prepaid expenses	`PrepaidExpenseCurrent`	$945.00M	USD	Point-in-time
Prepaid expenses	`PrepaidExpenseCurrent`	$1.07B	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$965.00M	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$710.00M	USD	Point-in-time
Assets held for sale	`AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent`	$189.00M	USD	Point-in-time
Assets held for sale	`AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent`	$19.00M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$12.57B	USD	Point-in-time
Total current assets	`AssetsCurrent`	$13.01B	USD	Point-in-time
Deferred income taxes	`DeferredIncomeTaxAssetsNet`	$596.00M	USD	Point-in-time
Deferred income taxes	`DeferredIncomeTaxAssetsNet`	$695.00M	USD	Point-in-time
Other non-current assets	`OtherAssetsNoncurrent`	$515.00M	USD	Point-in-time
Other non-current assets	`OtherAssetsNoncurrent`	$538.00M	USD	Point-in-time
Property, plant and equipment, net	`PropertyPlantAndEquipmentNet`	$6.30B	USD	Point-in-time
Property, plant and equipment, net	`PropertyPlantAndEquipmentNet`	$5.98B	USD	Point-in-time
Operating lease right-of-use assets	`OperatingLeaseRightOfUseAsset`	$559.00M	USD	Point-in-time
Operating lease right-of-use assets	`OperatingLeaseRightOfUseAsset`	$495.00M	USD	Point-in-time
Identifiable intangible assets, net	`FiniteLivedIntangibleAssetsNet`	$8.92B	USD	Point-in-time
Identifiable intangible assets, net	`FiniteLivedIntangibleAssetsNet`	$7.47B	USD	Point-in-time
Goodwill	`Goodwill`	$20.04B	USD	Point-in-time
Goodwill	`Goodwill`	$20.62B	USD	Point-in-time
Goodwill	`Goodwill`	$24.85B	USD	Point-in-time
Total assets	`Assets`	$50.64B	USD	Point-in-time
Total assets	`Assets`	$47.67B	USD	Point-in-time
Short-term debt	`DebtCurrent`	$1.43B	USD	Point-in-time
Short-term debt	`DebtCurrent`	$3.19B	USD	Point-in-time
Sales reserves and allowances	`SalesReservesAndAllowances`	$4.24B	USD	Point-in-time
Sales reserves and allowances	`SalesReservesAndAllowances`	$4.82B	USD	Point-in-time
Accounts payables	`AccountsPayableTradeCurrent`	$1.76B	USD	Point-in-time
Accounts payables	`AccountsPayableTradeCurrent`	$1.69B	USD	Point-in-time
Employee-related obligations	`EmployeeRelatedLiabilitiesCurrent`	$563.00M	USD	Point-in-time
Employee-related obligations	`EmployeeRelatedLiabilitiesCurrent`	$685.00M	USD	Point-in-time
Accrued expenses	`AccruedExpenses`	$2.21B	USD	Point-in-time
Accrued expenses	`AccruedExpenses`	$1.78B	USD	Point-in-time
Other current liabilities	`OtherLiabilitiesCurrent`	$933.00M	USD	Point-in-time
Other current liabilities	`OtherLiabilitiesCurrent`	$903.00M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$13.16B	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$11.03B	USD	Point-in-time
Deferred income taxes	`DeferredTaxAndOtherLiabilitiesNoncurrent`	$784.00M	USD	Point-in-time
Deferred income taxes	`DeferredTaxAndOtherLiabilitiesNoncurrent`	$964.00M	USD	Point-in-time
Other taxes and long-term liabilities	`OtherLiabilitiesNoncurrent`	$2.58B	USD	Point-in-time
Other taxes and long-term liabilities	`OtherLiabilitiesNoncurrent`	$2.24B	USD	Point-in-time
Senior notes and loans	`LongTermNotesAndLoans`	$21.62B	USD	Point-in-time
Senior notes and loans	`LongTermNotesAndLoans`	$22.73B	USD	Point-in-time
Operating lease liabilities	`OperatingLeaseLiabilityNoncurrent`	$479.00M	USD	Point-in-time
Operating lease liabilities	`OperatingLeaseLiabilityNoncurrent`	$416.00M	USD	Point-in-time
Total long-term liabilities	`LiabilitiesNoncurrent`	$25.39B	USD	Point-in-time
Total long-term liabilities	`LiabilitiesNoncurrent`	$26.41B	USD	Point-in-time
Commitments and contingencies, see note 12	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingencies, see note 12	`CommitmentsAndContingencies`	-	USD	Point-in-time
Total liabilities	`Liabilities`	$39.58B	USD	Point-in-time
Total liabilities	`Liabilities`	$36.42B	USD	Point-in-time
Ordinary shares of NIS 0.10 par value per share; December 31, 2021 and December 31, 2020: authorized 2,495 million shares; issued 1,209 million shares and 1,202 million shares, respectively	`CommonStockValue`	$57.00M	USD	Point-in-time
Ordinary shares of NIS 0.10 par value per share; December 31, 2021 and December 31, 2020: authorized 2,495 million shares; issued 1,209 million shares and 1,202 million shares, respectively	`CommonStockValue`	$57.00M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$27.56B	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$27.44B	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-10.95B	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-10.53B	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-2.68B	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-2.40B	USD	Point-in-time
Treasury shares as of December 31, 2021 and December 31, 2020: 106 million ordinary shares	`TreasuryStockValue`	$4.13B	USD	Point-in-time
Treasury shares as of December 31, 2021 and December 31, 2020: 106 million ordinary shares	`TreasuryStockValue`	$4.13B	USD	Point-in-time
Stockholders' equity attributable to Teva shareholders	`StockholdersEquity`	$10.03B	USD	Point-in-time
Stockholders' equity attributable to Teva shareholders	`StockholdersEquity`	$10.28B	USD	Point-in-time
Non-controlling interests	`MinorityInterest`	$1.03B	USD	Point-in-time
Non-controlling interests	`MinorityInterest`	$966.00M	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$11.24B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$15.06B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$15.79B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$11.06B	USD	Point-in-time
Total liabilities and equity	`LiabilitiesAndStockholdersEquity`	$47.67B	USD	Point-in-time
Total liabilities and equity	`LiabilitiesAndStockholdersEquity`	$50.64B	USD	Point-in-time

Income Statement 69 line items

Line Item	Tag	Value	Unit	Period
Net revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$16.66B	USD	Annual
Net revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$15.88B	USD	Annual
Net revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$16.89B	USD	Annual
Cost of sales	`CostOfGoodsAndServicesSold`	$8.28B	USD	Annual
Cost of sales	`CostOfGoodsAndServicesSold`	$8.93B	USD	Annual
Cost of sales	`CostOfGoodsAndServicesSold`	$9.35B	USD	Annual
Gross profit	`GrossProfit`	$7.59B	USD	Annual
Gross profit	`GrossProfit`	$7.54B	USD	Annual
Gross profit	`GrossProfit`	$7.73B	USD	Annual
Research and development expenses, net	`ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost`	$967.00M	USD	Annual
Research and development expenses, net	`ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost`	$997.00M	USD	Annual
Research and development expenses, net	`ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost`	$1.01B	USD	Annual
Selling and marketing expenses	`SellingAndMarketingExpense`	$2.50B	USD	Annual
Selling and marketing expenses	`SellingAndMarketingExpense`	$2.61B	USD	Annual
Selling and marketing expenses	`SellingAndMarketingExpense`	$2.43B	USD	Annual
General and administrative expenses	`GeneralAndAdministrativeExpense`	$1.19B	USD	Annual
General and administrative expenses	`GeneralAndAdministrativeExpense`	$1.10B	USD	Annual
General and administrative expenses	`GeneralAndAdministrativeExpense`	$1.17B	USD	Annual
Intangible assets impairments	`IntangibleAssetsImpairments`	$424.00M	USD	Annual
Intangible assets impairments	`IntangibleAssetsImpairments`	$1.50B	USD	Annual
Intangible assets impairments	`IntangibleAssetsImpairments`	$1.64B	USD	Annual
Goodwill impairment	`GoodwillImpairmentLoss`	-	USD	Annual
Goodwill impairment	`GoodwillImpairmentLoss`	$4.63B	USD	Annual
Goodwill impairment	`GoodwillImpairmentLoss`	-	USD	Annual
Other asset impairments, restructuring and other items	`ImpairmentsRestructuringAndOthers`	$423.00M	USD	Annual
Other asset impairments, restructuring and other items	`ImpairmentsRestructuringAndOthers`	$479.00M	USD	Annual
Other asset impairments, restructuring and other items	`ImpairmentsRestructuringAndOthers`	$341.00M	USD	Annual
Legal settlements and loss contingencies	`LegalSettlementsAndLossContingencies`	$60.00M	USD	Annual
Legal settlements and loss contingencies	`LegalSettlementsAndLossContingencies`	$717.00M	USD	Annual
Legal settlements and loss contingencies	`LegalSettlementsAndLossContingencies`	$1.18B	USD	Annual
Other income	`OtherOperatingIncomeExpenseNet`	$40.00M	USD	Annual
Other income	`OtherOperatingIncomeExpenseNet`	$76.00M	USD	Annual
Other income	`OtherOperatingIncomeExpenseNet`	$98.00M	USD	Annual
Operating (loss) income	`OperatingIncomeLoss`	$-443.00M	USD	Annual
Operating (loss) income	`OperatingIncomeLoss`	$1.72B	USD	Annual
Operating (loss) income	`OperatingIncomeLoss`	$-3.57B	USD	Annual
Financial expensesnet	`NonoperatingIncomeExpense`	$-834.00M	USD	Annual
Financial expensesnet	`NonoperatingIncomeExpense`	$-1.06B	USD	Annual
Financial expensesnet	`NonoperatingIncomeExpense`	$-822.00M	USD	Annual
Income (loss) before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$658.00M	USD	Annual
Income (loss) before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-4.41B	USD	Annual
Income (loss) before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-1.26B	USD	Annual
Income taxes (benefit)	`IncomeTaxExpenseBenefit`	$211.00M	USD	Annual
Income taxes (benefit)	`IncomeTaxExpenseBenefit`	$-278.00M	USD	Annual
Income taxes (benefit)	`IncomeTaxExpenseBenefit`	$-168.00M	USD	Annual
Share in (profits) losses of associated companiesnet	`IncomeLossFromEquityMethodInvestments`	$138.00M	USD	Annual
Share in (profits) losses of associated companiesnet	`IncomeLossFromEquityMethodInvestments`	$9.00M	USD	Annual
Share in (profits) losses of associated companiesnet	`IncomeLossFromEquityMethodInvestments`	$-13.00M	USD	Annual
Net income (loss)	`ProfitLoss`	$456.00M	USD	Annual
Net income (loss)	`ProfitLoss`	$-1.00B	USD	Annual
Net income (loss)	`ProfitLoss`	$-4.10B	USD	Annual
Net income (loss) attributable to non-controlling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$-109.00M	USD	Annual
Net income (loss) attributable to non-controlling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$-2.00M	USD	Annual
Net income (loss) attributable to non-controlling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$39.00M	USD	Annual
Net income (loss) attributable to Teva	`NetIncomeLoss`	$-999.00M	USD	Annual
Net income (loss) attributable to Teva	`NetIncomeLoss`	$417.00M	USD	Annual
Net income (loss) attributable to Teva	`NetIncomeLoss`	$-3.99B	USD	Annual
Basic	`EarningsPerShareBasic`	$-0.91	USD	Annual
Basic	`EarningsPerShareBasic`	$0.38	USD	Annual
Basic	`EarningsPerShareBasic`	$-3.64	USD	Annual
Diluted	`EarningsPerShareDiluted`	$-3.64	USD	Annual
Diluted	`EarningsPerShareDiluted`	$0.38	USD	Annual
Diluted	`EarningsPerShareDiluted`	$-0.91	USD	Annual
Basic	`WeightedAverageNumberOfSharesOutstandingBasic`	1.10B	shares	Annual
Basic	`WeightedAverageNumberOfSharesOutstandingBasic`	1.09B	shares	Annual
Basic	`WeightedAverageNumberOfSharesOutstandingBasic`	1.09B	shares	Annual
Diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	1.09B	shares	Annual
Diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	1.11B	shares	Annual
Diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	1.09B	shares	Annual

Cash Flow Statement 123 line items

Line Item	Tag	Value	Unit	Period
Net income (loss)	`ProfitLoss`	$456.00M	USD	Annual
Net income (loss)	`ProfitLoss`	$-1.00B	USD	Annual
Net income (loss)	`ProfitLoss`	$-4.10B	USD	Annual
Impairment of goodwill, long-lived assets and assets held for sale	`AssetImpairmentCharges`	$584.00M	USD	Annual
Impairment of goodwill, long-lived assets and assets held for sale	`AssetImpairmentCharges`	$1.78B	USD	Annual
Impairment of goodwill, long-lived assets and assets held for sale	`AssetImpairmentCharges`	$6.55B	USD	Annual
Depreciation and amortization	`DepreciationAndAmortization`	$1.33B	USD	Annual
Depreciation and amortization	`DepreciationAndAmortization`	$1.56B	USD	Annual
Depreciation and amortization	`DepreciationAndAmortization`	$1.72B	USD	Annual
Net change in operating assets and liabilities	`IncreaseDecreaseInOperatingCapital`	$896.00M	USD	Annual
Net change in operating assets and liabilities	`IncreaseDecreaseInOperatingCapital`	$1.70B	USD	Annual
Net change in operating assets and liabilities	`IncreaseDecreaseInOperatingCapital`	$2.19B	USD	Annual
Deferred income taxesnet and uncertain tax positions	`DeferredIncomeTaxesNetAndUncertainTaxPositions`	$-985.00M	USD	Annual
Deferred income taxesnet and uncertain tax positions	`DeferredIncomeTaxesNetAndUncertainTaxPositions`	$-696.00M	USD	Annual
Deferred income taxesnet and uncertain tax positions	`DeferredIncomeTaxesNetAndUncertainTaxPositions`	$-120.00M	USD	Annual
Stock-based compensation	`ShareBasedCompensation`	$119.00M	USD	Annual
Stock-based compensation	`ShareBasedCompensation`	$119.00M	USD	Annual
Stock-based compensation	`ShareBasedCompensation`	$129.00M	USD	Annual
Other items	`OtherOperatingActivitiesCashFlowStatement`	$100.00M	USD	Annual
Other items	`OtherOperatingActivitiesCashFlowStatement`	$16.00M	USD	Annual
Other items	`OtherOperatingActivitiesCashFlowStatement`	$28.00M	USD	Annual
Research and development in process	`ResearchAndDevelopmentInProcess`	$80.00M	USD	Annual
Research and development in process	`ResearchAndDevelopmentInProcess`	$10.00M	USD	Annual
Research and development in process	`ResearchAndDevelopmentInProcess`	-	USD	Annual
Net loss (gain) from investments and from sale of business and long lived assets	`ProfitFromSaleOfLongLivedAssetsAndInvestment`	$213.00M	USD	Annual
Net loss (gain) from investments and from sale of business and long lived assets	`ProfitFromSaleOfLongLivedAssetsAndInvestment`	$-104.00M	USD	Annual
Net loss (gain) from investments and from sale of business and long lived assets	`ProfitFromSaleOfLongLivedAssetsAndInvestment`	$18.00M	USD	Annual
Net cash provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$1.22B	USD	Annual
Net cash provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$798.00M	USD	Annual
Net cash provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$748.00M	USD	Annual
Beneficial interest collected in exchange for securitized trade receivables	`ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables`	$1.49B	USD	Annual
Beneficial interest collected in exchange for securitized trade receivables	`ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables`	$1.65B	USD	Annual
Beneficial interest collected in exchange for securitized trade receivables	`ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables`	$1.41B	USD	Annual
Proceeds from sale of business and long lived assets	`ProceedsFromDivestitureOfBusinesses`	$311.00M	USD	Annual
Proceeds from sale of business and long lived assets	`ProceedsFromDivestitureOfBusinesses`	$343.00M	USD	Annual
Proceeds from sale of business and long lived assets	`ProceedsFromDivestitureOfBusinesses`	$67.00M	USD	Annual
Purchases of property, plant and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$562.00M	USD	Annual
Purchases of property, plant and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$525.00M	USD	Annual
Purchases of property, plant and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$578.00M	USD	Annual
Purchases of investments and other assets	`PaymentToAcquireMarketableSecuritiesAndOtherAssets`	$55.00M	USD	Annual
Purchases of investments and other assets	`PaymentToAcquireMarketableSecuritiesAndOtherAssets`	$8.00M	USD	Annual
Purchases of investments and other assets	`PaymentToAcquireMarketableSecuritiesAndOtherAssets`	$47.00M	USD	Annual
Proceeds from sale of investments	`ProceedsFromSaleMaturityAndCollectionsOfInvestments`	$2.00M	USD	Annual
Proceeds from sale of investments	`ProceedsFromSaleMaturityAndCollectionsOfInvestments`	$12.00M	USD	Annual
Proceeds from sale of investments	`ProceedsFromSaleMaturityAndCollectionsOfInvestments`	$172.00M	USD	Annual
Other investing activities	`PaymentsForProceedsFromOtherInvestingActivities`	$-1.00M	USD	Annual
Other investing activities	`PaymentsForProceedsFromOtherInvestingActivities`	$-56.00M	USD	Annual
Other investing activities	`PaymentsForProceedsFromOtherInvestingActivities`	$-12.00M	USD	Annual
Net cash provided by investing activities	`NetCashProvidedByUsedInInvestingActivities`	$1.52B	USD	Annual
Net cash provided by investing activities	`NetCashProvidedByUsedInInvestingActivities`	$1.35B	USD	Annual
Net cash provided by investing activities	`NetCashProvidedByUsedInInvestingActivities`	$863.00M	USD	Annual
Repayment of senior notes and loans and other long-term liabilities	`RepaymentsOfLongTermDebt`	$6.65B	USD	Annual
Repayment of senior notes and loans and other long-term liabilities	`RepaymentsOfLongTermDebt`	$3.94B	USD	Annual
Repayment of senior notes and loans and other long-term liabilities	`RepaymentsOfLongTermDebt`	$1.87B	USD	Annual
Proceeds from senior notes, net of issuance costs	`ProceedsFromDebtNetOfIssuanceCosts`	$4.97B	USD	Annual
Proceeds from senior notes, net of issuance costs	`ProceedsFromDebtNetOfIssuanceCosts`	$2.08B	USD	Annual
Proceeds from senior notes, net of issuance costs	`ProceedsFromDebtNetOfIssuanceCosts`	-	USD	Annual
Proceeds from short term debt	`ProceedsFromShortTermDebt`	$550.00M	USD	Annual
Proceeds from short term debt	`ProceedsFromShortTermDebt`	$700.00M	USD	Annual
Proceeds from short term debt	`ProceedsFromShortTermDebt`	$500.00M	USD	Annual
Repayment of short term debt	`RepaymentsOfShortTermDebt`	$700.00M	USD	Annual
Repayment of short term debt	`RepaymentsOfShortTermDebt`	$502.00M	USD	Annual
Repayment of short term debt	`RepaymentsOfShortTermDebt`	$559.00M	USD	Annual
Redemption of convertible debentures	`DebtConversionConvertedInstrumentAmount1`	-	USD	Annual
Redemption of convertible debentures	`DebtConversionConvertedInstrumentAmount1`	$491.00M	USD	Annual
Redemption of convertible debentures	`DebtConversionConvertedInstrumentAmount1`	-	USD	Annual
Other financing activities	`ProceedsFromPaymentsForOtherFinancingActivities`	$-5.00M	USD	Annual
Other financing activities	`ProceedsFromPaymentsForOtherFinancingActivities`	$-11.00M	USD	Annual
Other financing activities	`ProceedsFromPaymentsForOtherFinancingActivities`	$-6.00M	USD	Annual
Tax withholding payments made on shares and dividends	`PaymentsRelatedToTaxWithholdingForSharesAndDividend`	$52.00M	USD	Annual
Tax withholding payments made on shares and dividends	`PaymentsRelatedToTaxWithholdingForSharesAndDividend`	-	USD	Annual
Tax withholding payments made on shares and dividends	`PaymentsRelatedToTaxWithholdingForSharesAndDividend`	-	USD	Annual
Net cash used in financing activities	`NetCashProvidedByUsedInFinancingActivities`	$-1.89B	USD	Annual
Net cash used in financing activities	`NetCashProvidedByUsedInFinancingActivities`	$-2.17B	USD	Annual
Net cash used in financing activities	`NetCashProvidedByUsedInFinancingActivities`	$-1.93B	USD	Annual
Translation adjustment on cash and cash equivalents	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$8.00M	USD	Annual
Translation adjustment on cash and cash equivalents	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$-128.00M	USD	Annual
Translation adjustment on cash and cash equivalents	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$16.00M	USD	Annual
Net change in cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$202.00M	USD	Annual
Net change in cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$21.00M	USD	Annual
Net change in cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$193.00M	USD	Annual
Balance of cash, cash equivalents and restricted cash at beginning of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.98B	USD	Point-in-time
Balance of cash, cash equivalents and restricted cash at beginning of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$2.18B	USD	Point-in-time
Balance of cash, cash equivalents and restricted cash at beginning of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$2.20B	USD	Point-in-time
Balance of cash, cash equivalents and restricted cash at beginning of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.78B	USD	Point-in-time
Balance of cash, cash equivalents and restricted cash at end of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.98B	USD	Point-in-time
Balance of cash, cash equivalents and restricted cash at end of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$2.18B	USD	Point-in-time
Balance of cash, cash equivalents and restricted cash at end of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$2.20B	USD	Point-in-time
Balance of cash, cash equivalents and restricted cash at end of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.78B	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$1.98B	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$2.18B	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$2.17B	USD	Point-in-time
Restricted cash included in other current assets	`RestrictedCashAndCashEquivalentsAtCarryingValue`	-	USD	Point-in-time
Restricted cash included in other current assets	`RestrictedCashAndCashEquivalentsAtCarryingValue`	-	USD	Point-in-time
Restricted cash included in other current assets	`RestrictedCashAndCashEquivalentsAtCarryingValue`	$33.00M	USD	Point-in-time
Total cash, cash equivalents and restricted cash shown in the statement of cash flows	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.98B	USD	Point-in-time
Total cash, cash equivalents and restricted cash shown in the statement of cash flows	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$2.18B	USD	Point-in-time
Total cash, cash equivalents and restricted cash shown in the statement of cash flows	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$2.20B	USD	Point-in-time
Total cash, cash equivalents and restricted cash shown in the statement of cash flows	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.78B	USD	Point-in-time
Beneficial interest obtained in exchange for securitized trade receivables	`BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables`	$1.40B	USD	Point-in-time
Beneficial interest obtained in exchange for securitized trade receivables	`BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables`	$1.64B	USD	Point-in-time
Beneficial interest obtained in exchange for securitized trade receivables	`BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables`	$1.51B	USD	Point-in-time
Interest	`InterestPaidNet`	$840.00M	USD	Annual
Interest	`InterestPaidNet`	$846.00M	USD	Annual
Interest	`InterestPaidNet`	$913.00M	USD	Annual
Income taxes, net of refunds	`IncomeTaxesPaidNet`	$552.00M	USD	Annual
Income taxes, net of refunds	`IncomeTaxesPaidNet`	$709.00M	USD	Annual
Income taxes, net of refunds	`IncomeTaxesPaidNet`	$495.00M	USD	Annual
Other current assets	`IncreaseDecreaseInOtherCurrentAssets`	$-2.27B	USD	Annual
Other current assets	`IncreaseDecreaseInOtherCurrentAssets`	$-1.42B	USD	Annual
Other current assets	`IncreaseDecreaseInOtherCurrentAssets`	$-1.47B	USD	Annual
Trade payables, accrued expenses, employee-related obligations and other liabilities	`IncreaseDecreaseInCertainCurrentLiabilitiesExcludingDebt`	$643.00M	USD	Annual
Trade payables, accrued expenses, employee-related obligations and other liabilities	`IncreaseDecreaseInCertainCurrentLiabilitiesExcludingDebt`	$764.00M	USD	Annual
Trade payables, accrued expenses, employee-related obligations and other liabilities	`IncreaseDecreaseInCertainCurrentLiabilitiesExcludingDebt`	$-463.00M	USD	Annual
Trade receivables net of sales reserves and allowances	`IncreaseDecreaseInCertainCurrentAssetsExcludingInventories`	$-394.00M	USD	Annual
Trade receivables net of sales reserves and allowances	`IncreaseDecreaseInCertainCurrentAssetsExcludingInventories`	$-293.00M	USD	Annual
Trade receivables net of sales reserves and allowances	`IncreaseDecreaseInCertainCurrentAssetsExcludingInventories`	$-574.00M	USD	Annual
Inventories	`IncreaseDecreaseInInventories`	$271.00M	USD	Annual
Inventories	`IncreaseDecreaseInInventories`	$41.00M	USD	Annual
Inventories	`IncreaseDecreaseInInventories`	$380.00M	USD	Annual
Net Change In Items Comprising Supplemental Disclosure Of Cash Flow Information	`NetChangeInItemsComprisingSupplementalDisclosureOfCashFlowInformation`	$-1.70B	USD	Annual
Net Change In Items Comprising Supplemental Disclosure Of Cash Flow Information	`NetChangeInItemsComprisingSupplementalDisclosureOfCashFlowInformation`	$-2.19B	USD	Annual
Net Change In Items Comprising Supplemental Disclosure Of Cash Flow Information	`NetChangeInItemsComprisingSupplementalDisclosureOfCashFlowInformation`	$-896.00M	USD	Annual

Stockholders Equity 23 line items

Line Item	Tag	Value	Unit	Period
Beginning balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$11.24B	USD	Point-in-time
Beginning balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$15.06B	USD	Point-in-time
Beginning balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$15.79B	USD	Point-in-time
Beginning balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$11.06B	USD	Point-in-time
Net income (loss)	`ProfitLoss`	$456.00M	USD	Annual
Net income (loss)	`ProfitLoss`	$-1.00B	USD	Annual
Net income (loss)	`ProfitLoss`	$-4.10B	USD	Annual
Other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$-30.00M	USD	Annual
Other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$-391.00M	USD	Annual
Other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$160.00M	USD	Annual
Issuance of Treasury Shares	`TreasuryStockValueAcquiredCostMethod`	$6.00M	USD	Annual
Issuance of Shares, value	`StockIssuedDuringPeriodValueNewIssues`	$1.00M	USD	Annual
Stock-based compensation expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$129.00M	USD	Annual
Stock-based compensation expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$119.00M	USD	Annual
Stock-based compensation expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$119.00M	USD	Annual
Transactions with non-controlling interests	`TransactionsWithNonControllingInterests`	$-8.00M	USD	Annual
Transactions with non-controlling interests	`TransactionsWithNonControllingInterests`	$-2.00M	USD	Annual
Transactions with non-controlling interests	`TransactionsWithNonControllingInterests`	$-2.00M	USD	Annual
Other	`OtherEquity`	$-8.00M	USD	Annual
Ending balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$11.24B	USD	Point-in-time
Ending balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$15.06B	USD	Point-in-time
Ending balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$15.79B	USD	Point-in-time
Ending balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$11.06B	USD	Point-in-time

Comprehensive Income 27 line items

Line Item	Tag	Value	Unit	Period
Net income (loss)	`ProfitLoss`	$456.00M	USD	Annual
Net income (loss)	`ProfitLoss`	$-1.00B	USD	Annual
Net income (loss)	`ProfitLoss`	$-4.10B	USD	Annual
Currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$97.00M	USD	Annual
Currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-69.00M	USD	Annual
Currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-462.00M	USD	Annual
Unrealized gain (loss) on derivative financial instruments, net	`UnrealizedGainLossOnDerivativeNetOfTax`	$39.00M	USD	Annual
Unrealized gain (loss) on derivative financial instruments, net	`UnrealizedGainLossOnDerivativeNetOfTax`	$84.00M	USD	Annual
Unrealized gain (loss) on derivative financial instruments, net	`UnrealizedGainLossOnDerivativeNetOfTax`	$57.00M	USD	Annual
Unrealized gain (loss) on available-for-sale securities, net	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	-	USD	Annual
Unrealized gain (loss) on available-for-sale securities, net	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-1.00M	USD	Annual
Unrealized gain (loss) on available-for-sale securities, net	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	-	USD	Annual
Unrealized gain (loss) on defined benefit plans, net	`OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax`	$-20.00M	USD	Annual
Unrealized gain (loss) on defined benefit plans, net	`OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax`	$32.00M	USD	Annual
Unrealized gain (loss) on defined benefit plans, net	`OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax`	$-18.00M	USD	Annual
Total other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$-30.00M	USD	Annual
Total other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$-391.00M	USD	Annual
Total other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$160.00M	USD	Annual
Total comprehensive income (loss)	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$65.00M	USD	Annual
Total comprehensive income (loss)	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-4.13B	USD	Annual
Total comprehensive income (loss)	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-840.00M	USD	Annual
Comprehensive income (loss) attributable to non-controlling interests	`ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest`	$-68.00M	USD	Annual
Comprehensive income (loss) attributable to non-controlling interests	`ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest`	$-53.00M	USD	Annual
Comprehensive income (loss) attributable to non-controlling interests	`ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest`	$12.00M	USD	Annual
Comprehensive income (loss) attributable to Teva	`ComprehensiveIncomeNetOfTax`	$133.00M	USD	Annual
Comprehensive income (loss) attributable to Teva	`ComprehensiveIncomeNetOfTax`	$-4.08B	USD	Annual
Comprehensive income (loss) attributable to Teva	`ComprehensiveIncomeNetOfTax`	$-852.00M	USD	Annual

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.